DelveInsight’s, Non-Small-Cell Lung Cancer Pipeline Insight 2023” report provides comprehensive insights about 135+ companies and 150+ pipeline drugs in the Non-Small-Cell Lung cancer pipeline landscape. It covers the Non-Small-Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Small-Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Non-Small-Cell Lung Cancer Pipeline Report

• DelveInsight’s Non-Small-Cell Lung Cancer pipeline report depicts a robust space with 135+ active players working to develop 150+ pipeline therapies for Non-Small-Cell Lung Cancer treatment.
• The leading companies working in the Non-Small-Cell Lung Cancer Market include BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, BridgeBio Pharma, Abbvie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others.
• Promising Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, Quemliclustat, Zimberelimab, and others.
• November 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for V940 and Pembrolizumab. The goal of this study is to evaluate V940 plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of completely resected (R0) Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator. A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer.
• November 2023 Daiichi Sankyo Inc. announced a study of Phase 3 clinical trials for DS-1062a and Docetaxel. This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations. This study will evaluate DS-1062a 6.0 mg/kg vs docetaxel 75 mg/m^2 in participants with advanced or metastatic NSCLC with or without actionable genomic alterations (AGAs). Participants without actionable genomic alterations must have been previously treated with platinum-based chemotherapy and α (anti)-programmed cell death 1 (PD-1)/α-programmed cell death ligand 1 (PD-L1) monoclonal antibody, either in combination or sequentially. Participants with AGA must have progressed on or after 1 platinum-containing therapy and 1 to 2 prior lines of approved targeted therapy for the applicable genomic alteration. The study will be divided into 3 periods: Screening Period, Treatment Period, and Follow-up Period.
• November 2023: AstraZeneca announced a study of Phase 3 clinical trials for Durvalumab, Oleclumab, and Monalizumab. This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT. A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy.
• November 2023: BeiGene announced a study of Phase 1 clinical trials for Tislelizumab IV and Tislelizumab SC. This is an open-label, multicenter, Phase 1 clinical study to evaluate the bioavailability of tislelizumab subcutaneous (SC) injection in the first-line treatment of participants with advanced or metastatic non-small cell lung cancer (NSCLC). This clinical study will be divided into 2 parts: dose/injection site exploration (Part 1) and dose expansion (Part 2).
• November 2023: EMD Serono Research & Development Institute Inc. announced a study of Phase 1 & 2 clinical trials for M1774 and Cemiplimab. This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor M1774 in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer (nsqNSCLC) that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies.
• November 2023 Arcus Biosciences Inc. announced a study of Phase 2 clinical trials for Domvanalimab, Etrumadenant, and Zimberelimab. This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer. The primary objective of this clinical study is to evaluate the efficacy of each combination therapy by assessing: 1) objective response rate (ORR) of participants with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and 2) progression free survival (PFS).

 

Request a sample and discover the recent advances in Non-Small-Cell Lung Cancer Treatment Drugs @ Non-Small-Cell Lung Cancer Pipeline Report

 

In the Non-Small-Cell Lung Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Small-Cell Lung cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Non-Small-Cell Lung Cancer Overview

Non-small-cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small-cell lung cancer (SCLC) and accounts for about 85% of all lung cancers. There are three kinds of NSCLC tumors: a) Adenocancer starts in cells inside air sacs that make mucus and other substances, often in the outer parts of your lungs. It’s the most common kind of lung cancer among both smokers and nonsmokers and people under 45.

 

Find out more about Non-Small-Cell Lung Cancer Therapeutics Assessment @ Non-Small-Cell Lung Cancer Preclinical and Discovery Stage Products

 

Non-Small-Cell Lung Cancer Emerging Drugs Profile

• Datopotamab deruxtecan: Daiichi Sankyo
• JDQ443: Novartis
• MRTX849: Mirati Therapeutics
• INBRX-106: Inhibrx

 

Non-Small-Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 135+ key companies which are developing the therapies for Non-Small-Cell Lung cancer (NSCLC). The Non-Small-Cell Lung Cancer companies which have their Non-Small-Cell Lung cancer (NSCLC) drug candidates in the most advanced stage, i.e. Phase III include Daiichi Sankyo.

 

DelveInsight’s Non-Small-Cell Lung Cancer Pipeline Report covers around 150+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Non-Small-Cell Lung cancer Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

 

Non-small-cell lung Cancer Pipeline Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

 

Learn more about the emerging Non-Small-Cell Lung Cancer Pipeline Therapies @ Non-Small-Cell Lung Cancer Clinical Trials Assessment

 

Scope of the Non-Small-Cell Lung Cancer Pipeline Report

• Coverage- Global
• Non-Small-Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Non-Small-Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Non-Small-Cell Lung Cancer Companies- BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, BridgeBio Pharma, Abbvie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others.
• Non-Small Cell Lung Cancer Pipeline Therapies- DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, Quemliclustat, Zimberelimab, and others.

 

Dive deep into rich insights for new drugs for Non-Small-Cell Lung Cancer Treatment, Visit @ Non-Small-Cell Lung Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Non-Small-Cell Lung cancer (NSCLC): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Non-Small-Cell Lung cancer (NSCLC)– DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase III)
8. Datopotamab deruxtecan: Daiichi Sankyo
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RMC-4630: REVOLUTION Medicines
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. GB 1211: BridgeBio Pharma
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. BBP 398: BridgeBio Pharma.
18. Drug profiles in the detailed report…..
19. Preclinical Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Non-Small-Cell Lung cancer (NSCLC) Key Companies
24. Non-Small-Cell Lung cancer (NSCLC) Key Products
25. Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs
26. Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers
27. Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion
28. Non-Small-Cell Lung cancer (NSCLC) Analyst Views
29. Non-Small-Cell Lung cancer (NSCLC) Key Companies
30. Appendix

 

For further information on the Non-Small-Cell Lung Cancer Pipeline therapeutics, reach out to Non-Small-Cell Lung Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services